Search results
Results from the WOW.Com Content Network
You are free: to share – to copy, distribute and transmit the work; to remix – to adapt the work; Under the following conditions: attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made.
The Prescribing Information follows one of two formats: "physician labeling rule" format or "old" (non-PLR) format. For "old" format labeling a "product title" may be listed first and may include the proprietary name (if any), the nonproprietary name, dosage form(s), and other information about the product. The other sections are as follows:
Pages in category "Drugs developed by Pfizer" The following 200 pages are in this category, out of approximately 240 total. This list may not reflect recent changes .
Fosmanogepix is an experimental antifungal drug being developed by Amplyx Pharmaceuticals (now currently by Pfizer and Basilea [1] [2]) It is being investigated for its potential to treat various fungal infections including aspergillosis, candidaemia, and coccidioidomycosis.
Dapsone by mouth was one of the first medications used to treat moderate to severe acne vulgaris, and is still occasionally prescribed for the treatment of severe cases. [11] [12] A topical form of dapsone is also effective with potentially less side effects. [13] It is unclear if the combination with pyrimethamine is useful in the prevention ...
Pfizer Inc (NYSE:PFE) is looking to build on the success of its COVID-19 vaccine rollout by introducing a direct-to-consumer medicines platform under the brand “Pfizer for All.” The move ...
Rivastigmine, an Alzheimer's treatment medication, was released in patch form in 2007 under the brand name Exelon. [ 14 ] In December 2019, Robert S. Langer and his team developed and patented a technique whereby transdermal patches could be used to label people with invisible ink in order to store medical information subcutaneously.
The Food and Drug Administration on Friday approved Pfizer’s treatment for a rare genetic bleeding disorder, making it the company’s first-ever gene therapy to win clearance in the U.S.